BRPI0615272A2 - inibidores de p38 map kinase e métodos para uso dos mesmos - Google Patents
inibidores de p38 map kinase e métodos para uso dos mesmosInfo
- Publication number
- BRPI0615272A2 BRPI0615272A2 BRPI0615272-4A BRPI0615272A BRPI0615272A2 BR PI0615272 A2 BRPI0615272 A2 BR PI0615272A2 BR PI0615272 A BRPI0615272 A BR PI0615272A BR PI0615272 A2 BRPI0615272 A2 BR PI0615272A2
- Authority
- BR
- Brazil
- Prior art keywords
- methods
- map kinase
- kinase inhibitors
- compounds
- nitrogen
- Prior art date
Links
- 102000002574 p38 Mitogen-Activated Protein Kinases Human genes 0.000 title abstract 3
- 108010068338 p38 Mitogen-Activated Protein Kinases Proteins 0.000 title abstract 3
- 239000002829 mitogen activated protein kinase inhibitor Substances 0.000 title abstract 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 3
- 229910052757 nitrogen Inorganic materials 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Cardiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Ophthalmology & Optometry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Molecular Biology (AREA)
- Hospice & Palliative Care (AREA)
- Reproductive Health (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychiatry (AREA)
- AIDS & HIV (AREA)
- Vascular Medicine (AREA)
- Diabetes (AREA)
Abstract
INIBIDORES DE P38 MAP KINASE E MéTODOS PARA USO DOS MESMOS. Compostos de fórmula la, lb, lo, ld, le, lf, lg ou ih: no qual X e Y são nitrogênio ou um de X e Y é nitrogênio e o outro é CR^ g^, e W, D, E, R^ 4^, R^ 5^, R^ 6^ e R^ g^ são conforme aqui definidos. Também revelados são métodos de produção dos compostos e métodos de uso dos compostos no tratamento de doenças mediadas por p38 MAP kinase.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US71200705P | 2005-08-25 | 2005-08-25 | |
PCT/EP2006/065335 WO2007023115A2 (en) | 2005-08-25 | 2006-08-16 | P38 map kinase inhibitors and methods for using the same |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0615272A2 true BRPI0615272A2 (pt) | 2009-08-04 |
Family
ID=37441925
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0615272-4A BRPI0615272A2 (pt) | 2005-08-25 | 2006-08-16 | inibidores de p38 map kinase e métodos para uso dos mesmos |
Country Status (13)
Country | Link |
---|---|
US (1) | US7608603B2 (pt) |
EP (1) | EP1919914A2 (pt) |
JP (1) | JP2009506009A (pt) |
KR (1) | KR20080039438A (pt) |
CN (1) | CN101248077B (pt) |
AR (1) | AR055133A1 (pt) |
AU (1) | AU2006283945A1 (pt) |
BR (1) | BRPI0615272A2 (pt) |
CA (1) | CA2620106A1 (pt) |
IL (1) | IL189382A0 (pt) |
MX (1) | MX2008002590A (pt) |
TW (1) | TW200740816A (pt) |
WO (1) | WO2007023115A2 (pt) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20110160232A1 (en) | 2007-10-04 | 2011-06-30 | Pingda Ren | Certain chemical entities and therapeutic uses thereof |
WO2009114874A2 (en) | 2008-03-14 | 2009-09-17 | Intellikine, Inc. | Benzothiazole kinase inhibitors and methods of use |
JP5547099B2 (ja) | 2008-03-14 | 2014-07-09 | インテリカイン, エルエルシー | キナーゼ阻害剤および使用方法 |
AU2009268611B2 (en) | 2008-07-08 | 2015-04-09 | Intellikine, Llc | Kinase inhibitors and methods of use |
US8476282B2 (en) | 2008-11-03 | 2013-07-02 | Intellikine Llc | Benzoxazole kinase inhibitors and methods of use |
PE20170003A1 (es) | 2009-08-17 | 2017-03-15 | Intellikine Llc | Compuestos heterociclicos y usos de los mismos |
EP2678018A4 (en) | 2011-02-23 | 2015-09-30 | Intellikine Llc | COMBINATION OF CHINESE HEMMER AND USES THEREOF |
WO2014153509A1 (en) | 2013-03-22 | 2014-09-25 | Millennium Pharmaceuticals, Inc. | Combination of catalytic mtorc 1/2 inhibitors and selective inhibitors of aurora a kinase |
CN106795124A (zh) * | 2014-10-30 | 2017-05-31 | 桑多斯股份公司 | 取代的1H‑吡唑并[3,4‑d]嘧啶类化合物的合成 |
US10342786B2 (en) | 2017-10-05 | 2019-07-09 | Fulcrum Therapeutics, Inc. | P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD |
MX2020003961A (es) | 2017-10-05 | 2020-09-22 | Fulcrum Therapeutics Inc | Uso de inhibidores de p38 para reducir la expresion de dux4. |
CN113194752A (zh) | 2018-06-01 | 2021-07-30 | 康奈尔大学 | Pi3k相关疾病或病症的组合疗法 |
JP7431435B2 (ja) * | 2019-11-14 | 2024-02-15 | 国立大学法人大阪大学 | 新規リゾホスファチジン酸誘導体 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6383790B1 (en) | 1999-01-11 | 2002-05-07 | Princeton University | High affinity protein kinase inhibitors |
KR200294211Y1 (ko) | 2002-07-26 | 2002-11-07 | 김관호 | 사각지대가 없는 자동차용 사이드 미러 |
US7135575B2 (en) * | 2003-03-03 | 2006-11-14 | Array Biopharma, Inc. | P38 inhibitors and methods of use thereof |
JP2007523938A (ja) * | 2004-02-27 | 2007-08-23 | エフ.ホフマン−ラ ロシュ アーゲー | ピラゾールの縮合誘導体 |
CA2619365A1 (en) * | 2005-08-22 | 2007-03-01 | Amgen Inc. | Pyrazolopyridine and pyrazolopyrimidine compounds useful as kinase enzymes modulators |
-
2006
- 2006-08-16 WO PCT/EP2006/065335 patent/WO2007023115A2/en active Application Filing
- 2006-08-16 CA CA002620106A patent/CA2620106A1/en not_active Abandoned
- 2006-08-16 JP JP2008527442A patent/JP2009506009A/ja not_active Ceased
- 2006-08-16 EP EP06778252A patent/EP1919914A2/en not_active Withdrawn
- 2006-08-16 MX MX2008002590A patent/MX2008002590A/es not_active Application Discontinuation
- 2006-08-16 KR KR1020087004487A patent/KR20080039438A/ko not_active Ceased
- 2006-08-16 AU AU2006283945A patent/AU2006283945A1/en not_active Abandoned
- 2006-08-16 CN CN2006800307579A patent/CN101248077B/zh not_active Expired - Fee Related
- 2006-08-16 BR BRPI0615272-4A patent/BRPI0615272A2/pt not_active Application Discontinuation
- 2006-08-22 TW TW095130750A patent/TW200740816A/zh unknown
- 2006-08-23 AR ARP060103656A patent/AR055133A1/es not_active Application Discontinuation
- 2006-08-23 US US11/509,121 patent/US7608603B2/en not_active Expired - Fee Related
-
2008
- 2008-02-07 IL IL189382A patent/IL189382A0/en unknown
Also Published As
Publication number | Publication date |
---|---|
US7608603B2 (en) | 2009-10-27 |
MX2008002590A (es) | 2008-03-18 |
CN101248077B (zh) | 2011-07-20 |
EP1919914A2 (en) | 2008-05-14 |
CA2620106A1 (en) | 2007-03-01 |
US20070049597A1 (en) | 2007-03-01 |
WO2007023115A3 (en) | 2007-04-12 |
JP2009506009A (ja) | 2009-02-12 |
CN101248077A (zh) | 2008-08-20 |
KR20080039438A (ko) | 2008-05-07 |
AU2006283945A1 (en) | 2007-03-01 |
WO2007023115A2 (en) | 2007-03-01 |
AR055133A1 (es) | 2007-08-08 |
TW200740816A (en) | 2007-11-01 |
IL189382A0 (en) | 2008-06-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0615272A2 (pt) | inibidores de p38 map kinase e métodos para uso dos mesmos | |
FIC20210022I1 (fi) | tukatinibi, valinnaisesti farmaseuttisesti hyväksyttävän suolan tai solvaatin muodossa | |
DE60214703D1 (de) | Thiazolverbindungen, die sich als inhibitoren von proteinkinasen eignen | |
ATE548363T1 (de) | 3,5-disubstituierte pyrid-2-one, die sich als inhibitoren der tec-familie von nicht-rezeptor- tyrosinkinasen eignen | |
ATE554087T1 (de) | Neue kinaseinhibitoren | |
EA200702347A1 (ru) | Способ получения глюкопиранозилзамещённых производных бензилбензола и промежуточных продуктов для их получения | |
ATE451376T1 (de) | Zusammensetzungen, die sich als inhibitoren von proteinkinasen eignen | |
ATE406351T1 (de) | Kondensierte heteroyralderivate zur verwendung als p38-kinase-inhibitoren | |
NO20076502L (no) | Pyrrolopyridiner nyttige som inhibitorer av proteinkinase | |
ATE432281T1 (de) | Pyrrolotriazin-kinasehemmer | |
NO20053470L (no) | Triazolopyridaziner som proteinkinase-inhibitorer | |
ATE419253T1 (de) | Inhibitoren von thienopyridin- und furopyridinkinase | |
ATE482213T1 (de) | Als inhibitoren von proteinkinasen geeignete pyrazoloä1,5-aüpyrimidine | |
ATE528302T1 (de) | 3,5-disubstituierte pyrid-2-one, die als hemmer der tec-familie von nicht-rezeptor tyrosin- kinasen nützlich sind | |
ATE469888T1 (de) | Indazol-, benzisoxazol- und benzisothiazol- kinaseinhibitoren | |
BRPI0509369A (pt) | azaindóis úteis como inibidores de jak e outras proteìna cinases | |
BR0313176A (pt) | Composições de pirazol úteis como inibidores de gsk-3 | |
CY1111138T1 (el) | Πυραζολο-υποκατεστημενες αμινοετεροαρυλ ενωσεις ως αναστολεις κινασης πρωτεϊνης | |
EA200901601A1 (ru) | Производные пиридазинона | |
ECSP066986A (es) | Beta-carbolinas utiles para tratar enfermedades inflamatorias | |
BR0215360A (pt) | Derivados de indolina úteis como inibidores de proteìna quinase | |
MX2008001538A (es) | Aril piridinas y metodos para su uso. | |
EA201000618A1 (ru) | 5-цианотиенопиридины для лечения опухолей | |
ATE389651T1 (de) | Als inhibitoren von c-met geeignete pyrrolzusammensetzungen | |
EP3912980A4 (en) | CYCLIC MOLECULES AS INHIBITORS OF BRUTON'S TYROSINE KINASE |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] |